FMP
Viridian Therapeutics, Inc.
VRDN
NASDAQ
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
14.6 USD
-0.56 (-3.84%)
About
ceo
Dr. Eric N. Olson Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.viridiantherapeutics.com
exchange
NASDAQ
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
CIK
0001590750
ISIN
US92790C1045
CUSIP
92790C104
Address
221 Crescent Street
Phone
617 272 4600
Country
US
Employee
94
IPO Date
Jun 18, 2014
Summary
CIK
0001590750
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92790C104
ISIN
US92790C1045
Country
US
Price
14.6
Beta
1.1
Volume Avg.
914.94k
Market Cap
916.41M
Shares
-
52-Week
10.925-30.3
DCF
1.79
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.75
P/B
-
Website
https://www.viridiantherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VRDN News
It looks like there's no news available.
